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Abstract
Background: The intersection of HIV-related health outcomes and problem substance use has been well
documented. New York City continues to be a focal point of the U.S. HIV epidemic. In 2011, the NYC Department of
Health and Mental Hygiene (NYC DOHMH) issued a recommendation that all HIV infected individuals should be
offered antiretroviral therapy (ART) regardless of CD4 cell count or other indicators of disease progression. This
policy is based in the concept of “treatment as prevention,” in which providing ART to people living with HIV
(PLWH) greatly reduces the likelihood of HIV transmission, while also improving individual health. The “ART for ALL”
(AFA) study was designed to inform modifications to and identify gaps in the implementation of universal ART, and
specifically to help guide allocation of resources to obtain local policy goals for increasing viral suppression among
PLWH who have problem substance use.
Methods/Design: The AFA Study is informed by two complementary frameworks: Glasgow and colleagues’ RE-AIM
model, a multi-level framework developed to guide the evaluation of implementation of new policies, and
Bronfrenbrenner’s ecological systems model, which conceptualizes the bi-directional interplay between people and
their environment. Using multi-level data and mixed methods, the primary aims of the AFA Study are to assess rates of
viral load suppression, using the NYC HIV Surveillance Registry, within 12 months of HIV diagnosis with (a) yearly
cohorts of high-risk-to-transmit, difficult-to-treat, substance using patients recruited from NYC Sexually Transmitted
Disease clinics and a large detoxification unit and (b) yearly cohorts of all newly HIV diagnosed people in NYC. Further
goals include (c) recruiting cross-sectional samples of HIV/AIDS service providers to assess ART initiation with problem
substance users and d) examining geographic factors that influence rates of viral load suppression. An Implementation
Collaborative Board meets regularly to guide study procedures and interpret results.
Discussion: The AFA Study has the unique strength of accessing and analyzing data at multiple levels using mixed
methodology, taking advantage of NYC DOHMH biomedical surveillance data. If successful, others may benefit from
lessons learned to inform local and state policies to improve the health of PLWH and further reduce HIV transmission.
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Background
The intersection of HIV-related health outcomes, such
as HIV transmission and substance abuse, has been well
documented. Problem substance is indicated in both HIV
prevention and treatment strategies. Beyond the risk of in-
creased rates of HIV transmission due to injection-related
behaviors (e.g., sharing needles), sex under the influence
of drugs and alcohol is frequently associated with HIV
transmission [1–6]. Persons with problem substance use
are also less likely to engage in treatment for HIV infec-
tion [7–9], to be retained in treatment [10], and to adhere
to antiretroviral treatment (ART) schedules [11, 12]. It is
also well established that substance users are at higher risk
for sexually transmitted infections (STI) [4, 13–15]. Preva-
lence of recent substance use in STI clinic samples include
up to 50 % reporting heavy alcohol use in the past 30 days
and 47 % with illicit substance use in the past year [16].
Sexually transmitted infections biologically facilitate HIV
transmission [17–19], and diagnosis of a sexually trans-
mitted infection is an indicator of risky sexual behavior.
Thus, ART initiation programs should target and respond
to the needs of substance users [20].
Shifting context of the NYC HIV epidemic
New York City continues to be a focal point of the U.S.
HIV epidemic; however, significant shifts in the epidemic
are underway. In 2010, there were 3353 new HIV infec-
tions in NYC [21]. As in the United States more broadly,
HIV infection in NYC is heavily concentrated in racial/
ethnic minority communities [10, 22]. In 2010, African
American/Black and Hispanic/Latino individuals made
up 47 and 31 %, respectively, of new HIV diagnoses in
NYC [21], while comprising 23 and 29 %, respectively, of
the NYC population [23]. Since 2010, there have been
continued decreases in the number of HIV diagnoses in
NYC. In 2013, there were a total of 2832 cases of new
HIV diagnoses in NYC, a reduction from 2990 in 2012
and 3225 in 2011 [21].
Viral load suppression within 12 months of diagnosis has
also been increasing over time. Data from 2006 to 2009 and
published in 2013 indicate that achieving viral suppression
(≤200 copies/mL) within 12 months of diagnosis was
39.8 % (36 % in 2006 and 45 % in 2009) [24]. More recently,
according to data from 2013, viral suppression within
12 months was 69 % [25]. This proportion was moderated
by age (younger people have lower rates of suppression)
and CD4 count at diagnosis (those with greater than 500
cells/mm3 were less likely to be suppressed) [25]. Durable
viral suppression (DVS), a marker of high engagement in
care, has also shown similar increases over the last decade.
Only 38.6 % of people living with HIV (PLWH) reached
DVS in 2006–2007, with DVS defined as all viral load tests
being ≤200 copies/mL over the 2 year period among people
with 2 or more viral load tests [26]. In 2010–2011, the
proportion with DVS had increased to 52 % - an overall
increase of 37 % from 2006–07 to 2010–11 [27].
Longitudinal data from a recent analysis of persons
who inject drugs, recruited from a large detoxification
unit and methadone maintenance program in NYC, also
demonstrated that the percentage of persons at risk for
transmitting HIV (defined as those HIV positive and en-
gaged in distributive needle sharing) decreased from 21 %
in 1990–1994 to 2 % in 2007–2014 [28]. These promising
trajectories suggest a shift in the HIV epidemic among
persons who inject drugs.
Despite these improvements, much work remains, es-
pecially among Black and Latino young men who have
sex with men (MSM) and individuals with problem sub-
stance use. To change the HIV landscape in a lasting
way at least 80 % of PLWH must be virally suppressed
[25, 29]. It is likely that additional innovative practices,
guidelines, and policies will be needed to increase the
proportion of PLWH who reach viral suppression within
12 months of diagnosis.
Universal antiretroviral therapy: treatment as prevention
In December 2011, the New York City Department of
Health and Mental Hygiene (NYC DOHMH) issued a
recommendation that all HIV infected individuals should
be offered ART regardless of CD4 cell count or other in-
dicators of disease progression [30]. This policy is based
in the concept of “treatment as prevention,” in which
providing ART to HIV seropositives greatly reduces the
likelihood of HIV transmission [31–34], while at the same
time improving individual health outcomes [35–37]. In
combination with other HIV prevention programs in New
York (e.g., Seek, Test, Treat, and Retain [20, 33, 38, 39],
free condom distribution, syringe exchange [40, 41], opioid
agonist treatment [42, 43], and most recently pre-exposure
prophylaxis [PrEP] for high-risk individuals)—the universal
ART policy aims to improve outcomes along the HIV care
cascade [44] and help to facilitate realization of an AIDS-
free generation.
NYC’s implementation of universal HIV treatment has
been gradual. Following the initial release of early treat-
ment recommendation in December 2011, there were ac-
companying press coverage and FAQ’s for providers and
consumers, revisions to the early treatment brochure dis-
tributed to testing and Ryan White funded clients (under-
or uninsured clients who receive federal funding for HIV
health care delivery), and the development of a texting
campaign for young MSM to encourage early treatment.
Universal ART was added to pre-existing efforts such
as the 2010 New York State law that health providers
of all types offer HIV testing to consumers aged 13–64
(and younger and older patients at high risk) at all visits
[45]. Multi-level, borough-wide campaigns using mass
media, provider training, community outreach, and other
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methods, urged HIV testing [46]. In 2013, the NYC
DOHMH Bureau of Sexually Transmitted Disease (STD)
Control assessed their HIV primary care referrals to en-
sure providers were implementing new recommendations
and, specifically that referrals were made only to providers
using universal ART guidelines. A primary initiative that
has recently been implemented by the NYC DOHMH is
to provide data on viral load and linkage to care to Health
and Hospitals Corporation and other high-volume HIV
care providers. Reporting of viral load outcomes will be a
critical feedback loop to providers for increasing aware-
ness of their patients’ outcomes and working to achieve
higher suppression rates.
Placing larger numbers of HIV diagnosed patients on
ART and providing support services so that they achieve
viral suppression will undoubtedly require additional re-
sources. The new policy will be incorporated into new
contracts between NYC DOHMH and AIDS service pro-
viders for use of Ryan White funds. These new contracts
will require that services be billed to Medicaid when
possible, so that Ryan White funds may be used for
those not Medicaid eligible (and who do not have private
health insurance).
Affordable care act legislation
Concurrent implementation of Patient Protection and
Affordable Care Act [47] legislation will also be an im-
portant factor in the evaluation of universal ART among
PLWH in NYC. The NYC DOHMH is in the process of
planning how to respond to the potential for the Afford-
able Care Act to alter the landscape of HIV treatment
and care, especially through Medicaid expansion and its
integration with state-based insurance exchanges. For
example, since Ryan White funding has a payment of
last resort requirement, Ryan White funded services will
need to adjust to the current implementation of Medic-
aid Health Homes, including income eligibility threshold
changes for Medicaid recipients and the implementation
of Health Insurance Exchanges.
An opportunity to evaluate the “ART for ALL” policy: AFA
study
In the context of a shifting HIV epidemic in NYC and
the overall changes across the healthcare continuum, the
“ART for ALL” (AFA) Study was designed to not only
provide critical information that could be used to help
achieve policy goals for increasing viral suppression
among PLWH, but to remain flexible within the chan-
ging context of the NYC HIV epidemic. The AFA Study
has the unique strength of accessing and analyzing data
at multiple levels, with mixed methods. It also has
the advantage of integrating NYC DOHMH biomedical
surveillance data, both with individual behavioral assess-
ments and geospatial (i.e., neighborhood) variables, to
provide information about potential moderators and medi-
ators of HIV treatment outcomes. Data collected from the
AFA Study will be used to inform modifications to or iden-
tify gaps in the implementation of universal ART, and in
particular, to help guide allocation of resources to obtain
local policy goals. The research will be conducted with the
NYC DOHMH as a full partner and includes a Collabora-
tive Board with service providers, clinical researchers, and
consumers to review data and make formal recommenda-
tions. If successful, there is potential that others may bene-
fit from lessons learned to improve the health of people
with HIV and reduce further HIV transmission – leading
the way towards an AIDS-free generation.
The primary aims of the AFA Study are to assess rates
of viral load suppression within 12 months of diagnosis
with (a) yearly cohorts of high risk to transmit, difficult
to treat, substance using patients and (b) yearly cohorts
of all newly HIV diagnosed people in NYC. Further goals
include (c) recruiting cross-sectional samples of HIV/
AIDS service providers to assess, via quantitative and
qualitative methods, ART initiation with problem sub-
stance users and organizational factors which facilitate
or impede ART initiation; and d) examining geographic
factors (i.e., United Hospital Fund (UHF) level data) that
influence rates of viral load suppression. NYC DOHMH
HIV surveillance data allow for the tracking of key clin-
ical outcomes (e.g., via viral load and CD4 count data).
The study is intended to inform implementation of the
universal ART policy, as well as treatment changes
brought about by the full implementation of the Affordable
Care Act, and guide allocation of resources to reach this
policy goal (see Fig. 1). As such, the AFA Study was pur-
posefully designed to be flexible and adjust to the changing
HIV landscape in NYC. The design, especially eliciting
ongoing Implementation Collaborative Board feedback,
also allows for modification of sampling and methods.
Methods/Design
Conceptual framework
The AFA Study is informed by two complementary
frameworks: the RE-AIM [48] and ecological systems
[49] models (see Fig. 2). The RE-AIM model [48] is a
multi-level framework developed to guide the evaluation
of implementation of new policies. RE-AIM is comprised
of five essential dimensions: 1) Reach – measure of per-
centage (and characteristics) of people who are affected
by the policy; 2) Efficacy – positive and negative individual
behavioral, quality of life, satisfaction, and physiologic
outcomes of the policy; 3) Adoption – proportion and
representativeness of participating and non-participating
providers/settings; 4) Implementation – extent to which
the policy or intervention is delivered as intended, in-
cluding participant adherence and provider fidelity;
and 5) Maintenance – long-term participant outcomes
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Fig. 1 AFA Study Implementation Timeline
Fig. 2 Ecological Systems and RE-AIM Conceptual Model
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and the extent to which policies become part of rou-
tine practice.
In this study, the RE-AIM model is utilized within the
context of the ecological systems model [49], which con-
ceptualizes the bi-directional interplay between people
and their environment. The ecological systems model is
useful for explaining syndemic health disparities associ-
ated with HIV (e.g., substance abuse, mental health,
sexually transmitted infections [50, 51] and specifically
how multi-level factors influence individual HIV treat-
ment linkage, retention, and ultimately viral load sup-
pression. Micro-level systems include the individual and
his/her immediate interpersonal interaction within family
or social supports, school, work, and services. “Proximal
processes”, or regular reciprocal interactions within an in-
dividual’s immediate environment that vary in duration,
frequency, interruption, timing, and intensity [52–54], are
an important part of the microsystem. The mesosystem is
comprised of interactions between microsystem settings.
Provider and organizational settings fall within the meso-
system (e.g., provider knowledge). The exosystem includes
dimensions of the larger social system in which the indi-
vidual is embedded, but over which he or she has limited
control. Place characteristics (e.g., poverty rates, the epide-
miologic environment, such as HIV prevalence, and the
health service environment, such as spatial access to
healthcare) are aspects of the exosystem. The macrosys-
tem covers overarching “prototypical” culture and struc-
tures (e.g., economic systems, social norms), often implicit
in social practice [55]. In the proposed study, micro, meso,
exo and macro system environments will be evaluated
among clients, providers, and the broader HIV treatment
system, including Affordable Care Act legislation.
Micro-system: STD/detox cohort and NYC surveillance
cohorts
Individual-level data will be obtained from two separate
cohorts: (1) STD/Detox and (2) HIV surveillance (i.e.,
all new HIV diagnoses in NYC). The STD/Detox cohort
allows for the collection of comprehensive data from a
subgroup of HIV-infected individuals, while the HIV
surveillance data allows for examination of the entire
population of newly HIV-infected individuals during
the study.
STD/detox cohort
The STD/Detox Cohort, as the name implies, will be re-
cruited from (1) NYC DOHMH STD clinics, primarily
from the two largest clinics located in Manhattan and
Brooklyn, and (2) the 139-bed inpatient general drug de-
toxification unit at Mount Sinai Beth Israel Medical
Center in Manhattan. Eligible participants 1) have a new
HIV diagnosis or have been previously diagnosed but
have been out of care in the last year (i.e., not seen by an
HIV primary care provider), 2) report problem substance
use, and 3) are able to speak and understand English. HIV
diagnoses will be confirmed through a match of study data
with the NYC DOHMH HIV surveillance registry. Problem
substance use is broadly defined to ensure range of severity:
injection drug use or injection drug use combined with
male to male HIV sexual transmission risk; illicit drug use
in the prior 12 months, including club drugs; or heavy
drinking (i.e., more than four drinks for men and more
than three drinks for women on one occasion, following
NIAAA guidelines [56]) in the past 30 days.
Recruitment locations were selected because these pa-
tients are likely to be at high-risk of transmitting HIV to
others (i.e., high rates of problem substance use [16] and
actively engaged in unsafe sexual behaviors) and they
will provide representation of a spectrum of substance
use problems – i.e. from more severe substance use dis-
orders on the detox unit to variable severity at the STD
clinics. Demographic profiles using prior research and
STD electronic medical record data from 2012 suggest
that 90 % of participants will be male; 55 % of STD clients
will be 29 years of age or younger, while the mean age of
detox clients will be 34 years and 35 % will identify as His-
panic, 31 % Black, and 27 % White [57]. In prior research,
younger HIV seropositive individuals have demonstrated
greater delay in treatment linkage [58].
Four yearly cohorts of patients are being recruited
(2014–2017; target N = 300, 75 per cohort). It is expected
that approximately 200 patients will be recruited from
STD clinics and 100 from detox. In 2011, 447 clients re-
ceived a positive test for HIV in NYC STD Clinics; 244
were from the two largest clinics (55 %). Approximately
4500 clients are seen in the Beth Israel Detox Program
each year; 10 % are HIV positive [28].
At first contact with the client, research staff will pro-
vide a brief description of the study and ask if the client
is willing to provide contact information. The research
assistant will contact interested clients by telephone and
will obtain the client’s verbal consent for a short screen-
ing interview. The screen will determine eligibility and
the following information will be collected: age, sex, gen-
der, race/ethnicity, transmission risk category, previous
HIV testing, and assessment of problem substance use.
Following screening, eligible and interested clients provide
written informed consent and are formally enrolled in the
study. All enrolled participants complete a baseline assess-
ment and four follow-up assessments at 6-month intervals
over the next two years. All measures will be administered
at all assessment time points (except for static demo-
graphic characteristics). All assessment visits will take
about 90 min. This study was approved by the Mount Sinai
St. Luke’s/Roosevelt Institutional Review Board (IRB),
Mount Sinai Beth Israel IRB, and the NYC DOHMH IRB.
Table 1 details domains, variables, and measurement tools
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Table 1 Measurement domains, variables, and data source by Ecological System and RE-AIM outcomes for patient, provider and
geographic analyses
Indicator/domain Variable(s) Measurement source
Patient level: Person (MICRO): Reach, Efficacy, Maintenance
Demographic
Characteristics
Age, race/ethnicity, sex, gender, marital status, living situation,
dependents, education and income, insurance, legal,




Durable Suppression: two consecutive tests with ≤ 200
HIV-1 RNA copies per mL of plasma
HIV Surveillance Registry
Viral Suppression: most recent test with ≤ 200 HIV-1 RNA
copies per mL of plasma
Secondary Outcome:
Linkage
Occurrence of first CD4/VL test date after study enrollment HIV Surveillance Registry
Secondary Outcome:
ART Initiation
ART regimen initiated AFA Survey
Secondary Outcome:
Treatment retention
Sustained engagement or regular care, ≥ 1 primary care





Adherent at threshold (≥90 %) for all ART medications Visual Analogue Scale [72–74]
Secondary Outcome:
Quality of Life
Health-related quality of life EQ-5D EuroQoL [75]
Secondary Outcome:
Sexual and Drug Use Risk
Sexual partners, unprotected sex acts, needle/works sharing Modified Risk Assessment Battery and Risk Behavior
Scale [76, 77]
Predictor: Substance Use Illicit drug use (days), alcohol (days, # drinks), substance
use disorder severity
TLFB [78]; QuickTox 8-panel Drug Screen Dipcard;
Fagerstrom Test for Nicotine Dependence [79]; DSM-V
Checklist for Substance Use Disorders [80]
Predictor: Mental Health Psychological distress Kessler10 [81], Personality Inventory for DSM-V Brief Form
[82]; Posttraumatic Stress Symptom Screener [80]




Medical, substance abuse treatment, mental health,
case management, Ryan White-funded services
Modified Treatment Services Review [85]
Predictor: Attitudes Attitudes towards primary HIV provider professional Attitudes Towards HIV Health Care Providers Scale [86];
Medical Mistrust Index [87]
Predictor: ART Barriers Barriers to ART adherence Adherence Barriers Questionnaire [88]
Predictor: Stigma Experiences and perceived discrimination and stigma MIDUS Daily Discrimination Scale [89]; Social Impact Scale [90]
Predictor: Knowledge HIV treatment knowledge HIV Treatment Related Knowledge Inventory [91, 92]
PROVIDER/PRIMARY CARE LEVEL (MESO): Adoption, Implementation, Maintenance
Professional
Characteristics
Age, sex, race/ethnicity, education, years since terminal





Location, service type, size, staffing, service flexibility, impact
of ACA, staff attributes, organizational culture and climate
Perceived Environmental Uncertainty (unpublished
measure, D’Aunno, 2013); Change Survey [93, 94]; Survey
of Organizational Attributes for Primary Care [95]; Medical
Group Practice Culture [96]
Predictor: Knowledge Knowledge of ART guidelines; perceived self-efficacy to
follow ART guidelines
AFA Survey
Predictor: Attitudes Attitudes and ideology toward patients and the provider/
patient relationship, including patients with substance
use problems
Attitudes About Patients with Substance Use Disorders
[97, 98]; Patient-Practitioner Orientation Scale [99]
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across data sources based on the RE-AIM dimensions. For
patient-level data collection, the dimensions Reach
and Efficacy will be assessed. Maintenance will be assessed
using patient follow-up data.
NYC HIV surveillance cohort
The HIV Surveillance data will serve as the source of
data for the STD/Detox patient-level outcomes, as well
as be used to create yearly NYC surveillance cohorts
(i.e., all new HIV positive individuals in NYC). The HIV
Epidemiology & Field Services Program at the NYC
DOHMH is authorized by the NYS Department of Health
to conduct HIV/AIDS surveillance in NYC. Diagnostic
providers are required by law to report all new diagnoses
of HIV and AIDS and all laboratories are required to
report positive HIV antibody tests (e.g., Western Blot,
Immunofluorescence Assay, Multispot) as well as all viral
loads, CD4 counts, and genetic resistance profiles. The
Data Support Unit in the HIV Epidemiology and Field
Services Program will assist with the matching of STD/
Detox patient information with registry data. Lab data are
prepared for import into the HIV registry through a rigor-
ous process that involves examining test information and
values for missing or erroneous data elements, cleaning
the data as needed, matching them against existing case
records, and standardizing key variables.
Because laboratories report patient viral loads over
time and because NYC DOHMH can identify each case
across time, it is possible to treat the surveillance data as
an open cohort that individuals enter when they are first
diagnosed with HIV. For example, we will use these data
to quantify the time interval between individuals’ HIV
diagnosis date and first viral load test as a marker for
HIV care initiation, as well as the interval between diag-
nosis date and viral suppression/durable suppression.
The HIV Surveillance Registry includes: date of birth;
sex; race/ethnicity; HIV transmission risk category; ZIP
code of residence at time of HIV/AIDS diagnosis; concur-
rent HIV/AIDS diagnosis (AIDS diagnosis within 31 days
of HIV diagnosis); vital status; viral load; and CD4 count.
Outcomes and analysis
The primary outcome variable for both the STD/Detox
and Surveillance cohorts is DVS within 12 months of
diagnosis, which will be calculated based on viral load
values in the HIV Surveillance Registry. Persons with DVS
will have: 1) at least two suppressed viral loads (≤200 cop-
ies/mL) within the first 12 months that are at least 90 days
apart; 2) no unsuppressed intervening viral loads; 3) no
unsuppressed viral load tests in the interval between
achievement of DVS and the end of the 12 month period.
The date of DVS will be based on the second suppressed
viral load test that qualifies that person as having DVS.
For the STD/Detox cohort, the DVS outcome will be
examined in two ways: more conservatively via a test of
significant improvement and a priori increase of ≥5 %,
and less conservatively to determine whether trends are
increasing. The first hypothesis is that the proportion of
subjects achieving DVS at each cohort year is different
than 52 % (the most recent DVS estimate at the time of
study development [27]). The hypothesis will be evaluated
each year using two-sided proportion z-test. With a sam-
ple size of 75 for each cohort, we have at least 80 % power
to detect viral suppression of 69 % using a 2-sided hypoth-
esis test with level of significance of 5 %. Thus, the univer-
sal ART policy will be considered to have contributed to
improved DVS if we reject the null hypothesis, because
the sample durable suppression proportion is significantly
greater than 52 %. Improvement will be considered incon-
clusive when the conclusion of the hypothesis test is ‘not
having enough evidence to reject null hypothesis’. It is
possible that viral suppression could worsen; this would
be indicated if we reject the null hypothesis and DVS in
the sample proportion is less than 52 %.
The second primary hypothesis is that the proportion
of subjects from the Surveillance cohort that achieve
DVS in each yearly cohort is different than 52 %. Be-
cause this cohort includes the entire population of newly
HIV diagnosed cases in NYC, the proportion of subjects
achieving DVS is considered a population proportion
and sampling statistical techniques are not applicable.
Therefore, an increase in population proportion of
Table 1 Measurement domains, variables, and data source by Ecological System and RE-AIM outcomes for patient, provider and
geographic analyses (Continued)
NEIGHBORHOOD/GEOGRAPHIC LEVEL (EXO): Reach, Efficacy, Maintenance
Predictor: Socioeconomic
Conditions
Poverty rate; median income; unemployment rate;
educational attainment; percent of residents who are
non-Hispanic White
2011 American Community Survey, 5-year estimate [100]
Predictor: Health Service Spatial access to HIV primary care 2013 Data pull from HIVMA, AAHIVM, NYSDOH AIDS Institute
Provider Database
Predictor: Social Disorder Off-premises alcohol outlet density; vacant housing 2009–2012 U.S. Census Bureau’s Zip Code Business Patterns
[101–103]; 2009–2010, 2012 USPS Delivery Stats Product
[104–106]
Predictor: Social Cohesion % of housing units leased; % households that moved
into the neighborhood in last year
2011 American Community Survey, 5-year estimate [107]
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subjects achieving suppression of ≥5 % will be consid-
ered epidemiologically meaningful. Finally, the third hy-
pothesis associated with the primary aims will assess the
increasing trend of the proportion of subjects achieving
DVS over the course of the study. The hypothesis is that
there will be a significant positive trend in the proportion
of subjects in the STD/Detox sample achieving DVS across
4 years of the study. This aim will be analyzed using the
Cochran-Armitage trend test, which is less conservative
than the analysis proposed to test the two previous hypoth-
eses and thus, has a larger chance of correctly detecting
successful policies. With 300 subjects, we have 80 % power
to detect an overall increase of 12 % from the current 52 %
(i.e., roughly 3 % every year).
Secondary outcomes
Secondary patient-level outcomes with the STD/Detox
cohort will follow other HIV treatment cascade mile-
stones: (1) Linkage to care (time to initial visit), (2) ART
initiation (time to initiation of ART), (3) HIV treatment
retention (sustained engagement of regular care defined as
1 or more primary care visits in 6 months, and (4) ART ad-
herence (self-report). Additional outcomes include quality
of life, sexual risk, and drug use risk. Additional co-
variate and predictor data is also being collected (see
Table 1). Hypotheses 1 and 3 above will also be ex-
amined with the Surveillance cohort.
Qualitative in-depth interviews
At the 6-month follow-up visit, STD/Detox cohort par-
ticipants will also complete a 30–45 min qualitative
interview (n = 60). Qualitative assessment will elicit rich
descriptions of participants’ experiences and motives in
their own terms and language and provide complemen-
tary and elaborative data [59, 60]. Major themes will be
compared and contrasted across cases over time and
data will be analyzed as they are generated. If theoret-
ical saturation is achieved for key themes before com-
pleting interviews, qualitative interviews will be
stopped. Re-allocation of resources to complete add-
itional qualitative interviews is an option should un-
anticipated events generate new questions.
Meso-system: HIV treatment providers and primary care
organizations
HIV primary care providers (N = 60) practicing in NYC
will be recruited to provide information on adoption and
implementation of HIV treatment policies and the im-
pact of Affordable Care Act policy changes. Eligible pro-
viders will 1) work as a primary HIV medical care
provider (i.e., physician, nurse practitioner, or physician’s
assistant) with at least one HIV/AIDS patient on case-
load (assessed at screening), and 2) be able to speak/
understand English. Providers are initially identified
through three publicly available lists (HIV Medicine As-
sociation [61], American Academy of HIV Medicine
[62], and the New York State AIDS Institute [63]),
randomly selected, and then matched as recent reporting
providers in the NYC HIV surveillance system (ordered
a viral load test in 2013 or 2014 that was reported to the
NYC DOHMH). Providers will be interviewed in two
cross-sectional cohorts covering Years 2-3 and Years 4-5
of the project. Providers are contacted by phone and
given a description of the study, invited to participate,
and, if interested, scheduled for a study visit. At the
scheduled meeting, written informed consent is obtained
prior to completing any research assessments.
Providers complete a brief survey and in-depth inter-
view which will take approximately 60–90 min. Table 1
displays a list of indicator domains and variables to be
assessed. Quantitative survey items include: personal
and professional demographics, program characteristics,
organizational level attitudes and beliefs (environmental
uncertainty, change-related commitment, decision-making,
stress, innovativeness, autonomy, information emphasis),
and patient attitudes (patients with substance use dis-
orders, patient-practitioner orientation). The qualitative
interview covers domains including: understanding of uni-
versal ART policy, process of working with newly diag-
nosed HIV-infected patients, role of substance use and
mental health in ART initiation, challenges and facilitators
to providing medical care to HIV-infected patients, chal-
lenging patient conversations, impact of the Affordable
Care Act, role of NYC and New York State in HIV pri-
mary care practice, and attitudes and practice with pre-
exposure prophylaxis (PrEP). Questions about PrEP were
included as it is an important form of HIV transmission
prevention for high risk populations including negative
partners of PLWH. For provider-level data collection, the
dimensions Adoption, Implementation, and Maintenance
will be assessed (see Table 1). Provider data will be used to
elucidate information regarding Adoption, Implementation
and Maintenance of ART guidelines and explore: barriers
and facilitators to ART initiation, retention, adherence,
and viral load suppression; and changes in practice and
attitudes over time.
Exo-system: neighborhood analysis
The purpose of the geospatial analyses is to examine the
relationships of UHF-level exposures (specifically, socio-
economic conditions, social disorder, social cohesion,
and spatial access to healthcare) to the key outcomes
among the HIV Surveillance Registry cohort and
patient-level STD/Detox cohort. Key outcomes include
DVS, viral suppression, and other indicators along the
HIV treatment cascade (linkage to care, ART initiation,
and HIV care retention). These outcomes will also be ex-
plored as a function of HIV transmission category and
among racial/ethnic subgroups.
Data sources
Existing administrative databases will be analyzed to de-
scribe UHF-level socioeconomic conditions (e.g., poverty
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rates, education); social disorder (e.g., alcohol outlet
density); social cohesion (e.g., percent housing units
leased); and spatial access to HIV-related services (e.g.,
HIV primary care). These environmental dimensions will
be ascertained using methods based on the investigator’s
prior work [64–68]. For both the STD/Detox cohort and
for the entire HIV Surveillance Registry cohort, ZIP code
of residence at HIV diagnosis will be obtained and
linked to the patients' UHF district. Each UHF district
consists of 3–9 adjacent zip codes that have similar
sociodemographic characteristics. The NYC DOHMH
uses these districts to track and analyze local patterns of
health outcomes and healthcare service delivery. Median
district population size is approximately 195,000 (range:
31,000–477,500). Similar to the comprehensive STD/De-
tox cohorts, Reach, Efficacy and Maintenance will be
assessed using all new diagnoses from the NYC DOHMH
HIV Surveillance Registry (see Table 1).
Analysis
Relationships between UHF characteristics and the out-
comes (i.e., viral suppression and DVS within 12 months
of diagnosis) will be investigated using exploratory data
analysis and multilevel modeling [69, 70]. Individuals
will be nested within UHF districts, and UHF level predic-
tors will be used to examine outcomes at the individual
level. The collection of extensive data on all subjects in
the STD/Detox cohort will allow for more comprehensive
examination. Hierarchical regression will be used to ex-
plore significant differences between participants who
achieve viral suppression and those who do not in both
the HIV Surveillance Registry cohort and STD/Detox co-
hort to identify what factors influence differences. Such
factors would potentially support reallocation of resources
to increase rates of viral suppression in NYC. If the rela-
tionships between place characteristics and outcomes in
the STD/Detox cohort data are similar to those found in
the Surveillance cohort, we will have greater confidence
that the relationships found among the smaller STD/
Detox cohort are true.
Exo/macro-system: policy
To document policy adaptation or changes that pertain
to NYC, materials related to HIV testing, treatment, and
prevention guidelines will be collected at the city, state
and national level. These materials will include, but are
not limited to, modifications to existing guidelines,
committee meeting minutes, and funding decisions.
Importantly, upcoming changes related to Affordable Care
Act implementation, including the role of Health Homes
for people living with HIV/AIDS, insurance exchanges,
Medicaid expansion, and the AIDS Drug Assistance
Program will be documented and assessed at the client,
provider and system levels. Insurance information (and
other payer data) will be collected from participants;
information will also be collected from providers about
reimbursement methods and how these impact patient
outcomes. Policies will be archived by date to link with
changes in client and provider level data.
Collaborative board
The Collaborative Board will provide the primary basis
of collaborative action for grant implementation, review
of ongoing data and analysis, and feedback and recom-
mendations on policy and practice guidelines related to
the HIV treatment cascade in NYC. The Board is com-
prised of HIV treatment providers, clinical researchers,
consumers living with HIV, and NYC DOHMH repre-
sentatives from the HIV Epidemiology and Field Services
Program, Bureau of STD Control, and the HIV Care and
Treatment Program. Study investigators will convene the
board, present project data updates, and facilitate discus-
sion. The investigative team and NYC DOHMH staff
will not be present during deliberation related to specific
recommendations, so that decisions remain independent
of the other research processes. However, including all
key stakeholders in dialogue is essential for understanding
the context of policy implementation. Board meetings
will be audio recorded for analytic purposes (except
recommendation deliberations); recommendations will
be collected and documented. The Board will meet
approximately twice per year.
Discussion
This study protocol is being implemented in the context
of major shifts in the local HIV epidemic, including de-
creasing HIV diagnosis rates. The changing context has
also resulted in a reframing of state policy. In June 2014,
New York State Governor Andrew Cuomo announced a
plan to effectively “End the HIV Epidemic” by reducing
the HIV incidence rate to below epidemic levels - from
approximately 3000 cases per year to 750 cases by 2020
[71]. The plan proposes to address the following three
objectives: (1) identify persons with HIV and link them
to health care; (2) retain persons in health care and get
them on ART to maximize viral suppression; and (3)
provide access to PrEP for high-risk persons. Following
this press release, the Governor appointed a Task Force
to develop a set of recommendations for achieving these
three objectives. The Task Force convened October 2014
through January 2015 and was comprised of over 60
community, advocacy, and academic/research experts,
including Drs. Des Jarlais, Remien, and Urbina, all in-
volved in the current project (a list of Task Force mem-
bers is available here: http://www.health.ny.gov/diseases/
aids/ending_the_epidemic/docs/members.pdf ). The final
“blueprint” recommendations from the Task Force were
approved on January 13, 2015 and were released to the
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public in April 2015. Recommendations come from four
subcommittees: care, data, housing and supportive ser-
vices, and prevention. The recommendation domains are
complementary to data collected in the AFA Study.
The ambitious New York State goal of “Ending the
Epidemic” relies in part on improvements in rates of viral
load suppression. The proposed research: (1) studies a
policy (universal ART) clearly aimed at ending the
epidemic; (2) utilizes a mixed method design and multi-
system data sources to evaluate the local success of the
policy and provide a broader and more contextual under-
standing of PLWH treatment experiences; (3) examines
neighborhood characteristics (e.g., poverty rates, social
cohesion, spatial access to HIV care) that may affect
the likelihood of reaching viral suppression and how
place characteristics could generate racial/ethnic dispar-
ities in HIV infection; (4) assesses the policy concurrent to
service changes brought about by the Affordable Care
Act; and (5) in partnership with the NYC DOHMH and
collaborative board members, will disseminate findings in
real time throughout the funding period in the context
of a rapidly changing environment. The innovative com-
ponents of this project should help to produce critical
public health information with broad reach.
Collaborative board recommendations
The changing context and encouraging shifts in the
NYC HIV epidemic suggest the need to expand the
focus of the AFA Study. At a discussion of the Collab-
orative Board in January 2015, there was consensus to
expand the objectives of the study to focus equal time
on facilitators of linkage to care, retention in care,
initiation of ART, and ultimately viral suppression. In line
with this shift in emphasis on what is working well, the
Collaborative Board also agreed with the plan to begin en-
rolling any persons with HIV, in addition to newly diag-
nosed and out of care persons with HIV. In this way,
those who are HIV positive and in care can share informa-
tion on what has facilitated and supported their successful
HIV care trajectories.
Limitations
Several limitations are worth noting in the design and
implementation of the study. First, although the NYC
DOHMH HIV Surveillance Registry is one of the best in
the nation, there are data reporting and processing lags
that affect the timeliness of viral load suppression ana-
lyses. An additional limitation to surveillance data is the
difficulty in identifying out-migration of HIV positive in-
dividuals who have moved away from the city. A third
limitation is the difficulty, already noted, in recruiting
newly HIV-diagnosed individuals among a reduced num-
ber of HIV diagnoses, as well as the challenge for pa-
tients to manage their new diagnosis and feel prepared
to participate in research at the same time. This recruit-
ment challenge could lead to a higher likelihood of non-
representative samples. Fourth, there is no consistent
definition of DVS in use; the definition proposed in the
AFA Study may differ from other reports. Finally, be-
cause neighborhood level data are based on previously
existing data sources, there may be placed-based con-
structs that are important but are unmeasurable because
data are unavailable.
Study status
The AFA Study received NIH funding in July 2013 and
will continue through March 2018. The first patient-level
STD/Detox cohort was recruited in 2014 and Cohort 2
(January-December 2015) recruitment is underway. Re-
cruitment of the first of two cross-sectional cohorts of
providers is also underway. Initial analysis and manuscript
development is underway to examine the proportion of
newly diagnosed individuals (2009–2012) who reach viral
load suppression and DVS within 12 months of diagnosis.
This will be an analysis of geographic (UHF-level) predic-
tors of viral load suppression as a function of HIV trans-
mission risk (i.e., injection drug use, heterosexual sexual
transmission, or male to male sexual transmission).
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